106 related articles for article (PubMed ID: 3796760)
21. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
Newby JC; Johnston SR; Smith IE; Dowsett M
Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
[TBL] [Abstract][Full Text] [Related]
22. [Results of anti-estrogen therapy in metastatic breast cancer (preliminary results). Part II].
Firusian N; Schmidt CG
Med Welt; 1977 Dec; 28(51-52):2065-7. PubMed ID: 414049
[No Abstract] [Full Text] [Related]
23. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic effect of tamoxifen versus combined tamoxifen and diethylstilboestrol in advanced breast cancer in postmenopausal women.
Mouridsen HT; Salimtschik M; Dombernowsky P; Gelshoj K; Palshof T; Rorth M; Daehnfeldt JL; Rose C
Eur J Cancer (1965); 1980; Suppl 1():107-10. PubMed ID: 7032918
[No Abstract] [Full Text] [Related]
25. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
26. Tamoxifen treatment and new-onset depression in breast cancer patients.
Lee KC; Ray GT; Hunkeler EM; Finley PR
Psychosomatics; 2007; 48(3):205-10. PubMed ID: 17478588
[TBL] [Abstract][Full Text] [Related]
27. Immunocytochemical determination of estrogen and progesterone receptors on 219 fine-needle aspirates of breast cancer. A prospective study.
Marrazzo A; Taormina P; Leonardi P; Lupo F; Filosto S
Anticancer Res; 1995; 15(2):521-6. PubMed ID: 7763033
[TBL] [Abstract][Full Text] [Related]
28. Anti-estrogen therapy for breast cancer: focus on tamoxifen.
Flynn KT; Durivage HJ
Oncol Nurs Forum; 1982; 9(4):21-5. PubMed ID: 6923414
[No Abstract] [Full Text] [Related]
29. Long-term survival in primary breast cancer: correlation with estrogen and progesterone receptor assay results and adjuvant tamoxifen therapy.
Chrapusta SJ; Giermek J; Pieńkowski T
Med Sci Monit; 2004 Oct; 10(10):CR577-86. PubMed ID: 15448598
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of estrogen dependency of human breast cancers. II. Clinical evaluation of tamoxifen in advanced primary and recurrent breast cancer.
Nishiki M; Yamane M; Amano K; Yasuda K; Okumichi T; Ezaki H
Hiroshima J Med Sci; 1984 Jun; 33(2):163-6. PubMed ID: 6480380
[No Abstract] [Full Text] [Related]
31. Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients.
Morgan LR
Semin Oncol; 1985 Mar; 12(1 Suppl 1):43-7. PubMed ID: 3975652
[TBL] [Abstract][Full Text] [Related]
32. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
33. Assessment of response to tamoxifen among Iraqi patients with advanced breast cancer.
al-Alwan NA; al-Kubaisy W; al-Rawaq K
East Mediterr Health J; 2000; 6(2-3):475-82. PubMed ID: 11556039
[TBL] [Abstract][Full Text] [Related]
34. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
36. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
[TBL] [Abstract][Full Text] [Related]
37. Influence of tamoxifen on the tumor content of steroid hormone receptors (ER, PgR and AR) in patients with primary breast cancer.
Lundgren S; Søreide JA; Lea OA
Anticancer Res; 1994; 14(3B):1313-6. PubMed ID: 8067700
[TBL] [Abstract][Full Text] [Related]
38. [Tamoxifen: modern drug therapy of estrogen-dependent breast tumors].
Jovanović-Mićić D; Beleslin DB; Nikolić SS
Med Pregl; 1996; 49(7-8):287-90. PubMed ID: 8926945
[TBL] [Abstract][Full Text] [Related]
39. Estrogen and progesterone receptors in the endometrium of postmenopausal breast cancer patients treated with tamoxifen and progestogens.
Cohen I; Altaras MM; Beyth Y; Shapira J; Figer A; Tepper R; Cordoba M; Yigal D; Bernheim J
Gynecol Oncol; 1997 Apr; 65(1):83-8. PubMed ID: 9103396
[TBL] [Abstract][Full Text] [Related]
40. Progesterone binding cyst protein in hormone receptor positive breast cancer; a predictive factor for effect of adjuvant tamoxifen treatment.
Søreide JA; Kolnes J; Skarstein A; Aas T; Kvinnsland S
Anticancer Res; 1994; 14(5B):2105-8. PubMed ID: 7840507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]